Table 3.
Therapeutic targets in acute ischemic stroke focused on modulating HT.
| Therapy | Target | Effect on ischemic stroke | References |
|---|---|---|---|
| 3K3A-APC (modified active protein C) | Protease-activated receptor 1 | Possible benefit of reduced and smaller hemorrhages. | (6) |
| Enlimomab | ICAM-1 | Associated with poor outcomes and increased HT | (7) |
| Edaravone | ROS | No benefit in reducing HT occurrence | (8) |
| Glycyrrhizin | HMGB1 | • In rat model decreased HT • No human trial yet | (9) |
| Minocycline | MMP-9 | No benefit | (10) |
| N-tert-butyl-α-phenylnitrone (PBN) | ROS | • In rat and rabbit models helped to decrease HT • No human trial yet | (11, 12) |
| NXY-059 | ROS | Found to be ineffective for preventing HT | (13) |
| Otaplimastat | MMP | Further investigation required | (14) |
HMGB1, high mobility group box protein 1; ICAM-1, intercellular adhesion molecule-1; MMP, matrix metalloproteinase; ROS, reactive oxygen species.